Investor Relations Home
|IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market.|
The Company was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, we changed our name to IRIDEX Corporation and reincorporated in Delaware. Investors and others should note that we announce material financial information to our investors using SEC filings, press releases, our investor relations website, public conference calls and webcasts. We use these channels as well as social media to communicate with investors, customers and the public about our company, our products and other issues. It is possible that the information we post on social media channels could be deemed to be material information. We encourage investors, our customers, and others interested in our company to review the information we post on our Facebook page (www.facebook.com/IRIDEX) and Twitter feed (https://twitter.com/IRIDEX).
|05/10/16||IRIDEX Announces Cyclo G6™ with MicroPulse® P3 Clinical Data Presented at ARVO and ASCRS Annual Meetings|
|Data underscore safety and efficacy of non-invasive tissue-sparing technology in patients with glaucoma
MOUNTAIN VIEW, Calif., May 10, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, today announced that data on its MicroPulse® P3 device powered by the Cyclo G6™ Glaucoma Laser System was presented at both the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual ... |
|05/05/16||IRIDEX Reports 2016 First Quarter Results|
|Record First Quarter Revenues
Revenues Up 11 Percent Versus First Quarter of 2015
MOUNTAIN VIEW, Calif., May 5, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 2, 2016.
Revenues were $11.9 million for the first quarter of 2016, up 11 percent from $10.8 million for the 2015 first quarter and a record for first quarter revenues.
Gross margin for the 2016 first quarter was 44.4 percent compared to 50.1 percen... |
|04/28/16||IRIDEX Announces First Quarter 2016 Conference Call and Release Date|
|MOUNTAIN VIEW, Calif., April 28, 2016 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its first quarter 2016 financial results after the market closes on Thursday, May 5, 2016. In conjunction with the release, the Company will host a conference call with the investment community at 5:00 p.m. Eastern Time on Thursday, May 5, 2016 to discuss the results of the quarter and other business developments.
Interested parties may access the live conference cal... |
|03/22/16||IRIDEX Gains Patent Approvals Covering TxCell™-Guided MicroPulse® Laser Therapy; Predictably Enables Faster, Durable Treatments for Glaucoma and Retinal Diseases|
|MOUNTAIN VIEW, Calif., March 22, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, announced today that the United States Patent Office issued the Company two new patent approvals for its recent submissions, covering key elements of its MicroPulse technology and improving the delivery of its sub-threshold treatment for patients with glaucoma and retinal diseases. The patents are relev... |
|Primary IR Contact|
President and CEO
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.